Publications found:
73,128
Sort by:
Celgene: Long-Term Prospects Intact but Competition Emerging!
US$ 140.00
... flat growth of Revlimid (L, RRMM, MDS), reported in its 1Q12, we expect Celgene (CELG) to meet its FY12 guidance (Total rev.: $5.4-$5.6b and EPS ... , please read our report, released on 12th June on CELG, titled “Long-Term Prospects Intact but Competition Emerging!”
June 2012
3 pages
Sanofi, ORIGIN TRIAL – No Implications, but removes the cancer risk overhang
US$ 90.00
The ORIGIN trial was intended to expand Lantus use in the ... existing use in the late stage setting. In the trial, Lantus did delay the progression of pre-diabetes to diabetes ... disadvantage. The only positive implication for Lantus from the ORIGIN trial is that it completely removes the cancer risk overhang on ...
June 2012
2 pages
The European League Against Rheumatism (EULAR) 2012 Noteworthy Takeaways
US$ 140.00
Among all oral options for the treatment of Rheumatoid Arthritis (RA), JAK inhibitors are ready to reach the market but the debate will continue – whether targeting specific JAK-1, 2, &3 or a multipronged approach like JAK 1/2, 1/3 is better? JAK1 may be the most suitable target as an anti-inflammatory drug ...
June 2012
10 pages
ELAN- A Tale of Two: Tysabri = Support; Bapineuzumab = Upside
US$ 300.00
... REMS program for PML risk have driven and anchored Elan Corp.'s (ELN), but future growth is highly dependant on the success ... , Please read our report released on June 11, 2012 on ELN, titled “A Tale of Two: Tysabri = Support; Bapineuzumab = Upside”.
June 2012
12 pages
VERTEX PHARMA - Time to Book Profits
US$ 140.00
Vertex (VRTX) has evolved from an innovator to a profitable Biotech but at the ... detail, please read our report released on 11th June, 2012 on Vertex titled “Time to Book Profits….!”
June 2012
4 pages
Novartis, ACZ885 – Impressive data in SJIA, but no meaningful commercial opportunity
US$ 90.00
Novartis today reported positive Phase 3 data on ACZ885 (canakinumab) in SJIA. The data is impressive but commercial opportunity would be limited as SJIA is a rare disease, while ... 20000 or less depending on the weight. While if NVS chose to price ACZ885 at its existing annual cost ($100,000), it may not be able ...
June 2012
1 pages
Life Sciences & Analytical Reagents Market Applications, Current Trends, Opportunities & Global Forecasts (2011 – 2016)
US$ 3,390.00
... ) & ANALYTICAL REAGENTS (Chromatography, Mass Spectrometry, Electrophoresis, Flow Cytometry) MARKET APPLICATIONS (Protein Purification, Gene Expression, DNA & RNA Analysis, & Drug Testing), CURRENT TRENDS, OPPORTUNITIES & GLOBAL FORECASTS (2011 – 2016) Biotechnology (life science and analytical) reagents are ...
June 2012
326 pages
China Healthcare Market Analysis
US$ 700.00
... participation. Although China healthcare market is fraction of the developed markets, it is actually witnessing double digit growth in recent years. However, within the Chinese healthcare market landscape,there ... increasing the healthcare expenditure’s percentage of the GDP. “China Healthcare Market Analysis” research report gives detailed overview on the multiple aspects related to healthcare system in China. It helps to understand ...
June 2012
94 pages
Erythropoietin Market Forecast to 2015
US$ 400.00
In the biopharmaceutical industry, protein-based therapies have become one of the most effective clinical methods to treat a wide spectrum of diseases, ranging from cancer to metabolic disorders. Acco...
June 2012
34 pages
Human Growth Hormone Market Forecast to 2015
US$ 400.00
Since the launch of human insulin product, protein-based therapies have found a prominent place in the biopharmaceutical industry. According to our new research report on Human Growth Hormone (HGH) Ma...
June 2012
34 pages
Indian Oral Care Market Forecast to 2015
US$ 250.00
In India, oral care segment holds a substantial share in the overall cosmetic market. On back of increasing awareness about oral hygiene, improving income, and high advertising expenditure by players,...
June 2012
26 pages
Interferon Market Forecast to 2015
US$ 400.00
One of the most effective clinical methods, used to treat a wide spectrum of diseases, protein-based therapies have found a prominent place in the biopharmaceutical industry. According to our new rese...
June 2012
37 pages
SUN PHARMA: Strong Quarter and Brighter Outlook
US$ 140.00
We reiterate Sun Pharma as our Top Pick in the Indian pharma space after its higher ... growth like (1) continuing sales of Doxil generic after Sun gets ANDA approval (2) launch of Prandin, Comtan ... In addition to the near term drivers, we see Sun Pharma positioning itself to become a leader in global generics with ...
May 2012
7 pages
IPCA- Ready to Fire from All Directions
US$ 140.00
IPCA’s Q4 FY12 result was slightly below our ... on Q-o-Q basis mainly due to the reduction in production as IPCA implemented the track and trace system in its manufacturing facility ... margin of 5%) too impacted the business. We remain enthused about Ipca’s 18-20% growth guidance for domestic pharma in FY13. We rate ...
May 2012
7 pages
CIPLA - Nothing New – As Expected
US$ 140.00
... ‘rationalization’ of various partnerships in different geographies. Launch of Dymista and Vancomycin by Cipla’s partners in US too may not fetch any meaningful upside in the ... near term. We reiterate our Market Perform on Cipla but change our target price to `341 as we rollover to FY13 ...
May 2012
7 pages
REGENERON - Diversified Pipeline can Buffer the Setback
US$ 140.00
Despite the setback in the pipeline – negative recommendation from FDA advisory committee on ... franchise should be able to buffer some setbacks in the pipeline. The FDA advisory panel voted 11-0 against approval of the ... , released on May 14, 2012 on REGN, titled “Diversified Pipeline can Buffer the Setback”.
May 2012
6 pages
CADILA HEALTHCARE - Nearing Inflection Point
US$ 140.00
Cadila’s Q4 FY12 result was much higher than our estimates owing to ... declined by 4.5% due to forex loss. FY12 remained a year of consolidation after Cadila acquired Nesher, Bremer and Biochem. Going forward, the company ...
May 2012
8 pages
INCYTE: JAKAFI / JAKAVI to Drive Sustainable Profitability
US$ 140.00
Incyte (INCY) reported net revenues of $19.3m of the only approved drug for Myelofribrosis (MF), JAKAFI / JAKAVI (ruxolitinib, JAK 1/2 inhibitor, PhII/III in PV/ET; partnered with Novartis for ... , please read our report released on May 2, 2012 on INCY, titled “JAKAFI / JAKAVI to Drive Sustainable Profitability”
May 2012
3 pages
Competitor Analysis: Janus Kinase (JAK) Inhibitors
US$ 394.00
... Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects from ... have been identified: JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2). JAK3 has attracted much attention as an anti-inflammatory drug target ...
May 2012
44 pages
India IVF Treatment Market Analysis
US$ 500.00
... , pelvic inflammatory diseases, etc. Today, arrays of treatment options to treat infertility are readily available in India. These include medications for ovulation induction ... IUI, IVF, and ICSI (intra cytoplasmic sperm injection). India has become one of the favored destinations for infertility treatments such as IVF due to several ...
May 2012
40 pages
Osteoporosis Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following Therapeutic Classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, ... 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 49 companies including many key and niche ...
May 2012
455 pages
China Healthcare Market Forecast to 2015
US$ 1,000.00
With the advancement of infrastructure, Chinese Healthcare Industry is entering into a new era of development. A large population-base along with increasing aging population, and continuously growing...
May 2012
135 pages
Global Trauma Market Report: 2012 Edition
US$ 800.00
The worldwide trauma market has experienced significant growth in the past and the market has considerable growth opportunity in the near future as the worldwide demand for trauma products is increasi...
May 2012
43 pages
Managing Investigator Initiated Research
US$ 595.00
... , and a fresh perspective on stakeholders’ roles and responsibilities. Report Overview Managing Investigator-Initiated Research This comprehensive report brings together industry data, exclusive ... end-to-end IIR programme management Who Would Benefit From This Report? Managers and Executives with responsibilities in: Investigator-initiated research (IIR) programmes Branding ...
May 2012
74 pages
Nutritional Supplements Market Report: 2012 Edition
US$ 800.00
... other countries like France and Denmark. The report provides an analysis of the global nutritional supplements market. It also discusses the major trends, ... growth drivers and challenges for the market. The report presents the ...
April 2012
40 pages
CELGENE – Revlimid Sales Disappoints, but Long Term Prospects Intact!
US$ 90.00
Though Q1’12 earnings were disappointing (flat growth of Revlimid), we expect Celgene (CELG) should able to meet its FY12 guidance (Total rev.: $5.4-$5.6b ... read our report released on 27th April, 2012 on CELG titled, “Revlimid Sales Disappoints, but Long Term Prospects Intact!”
April 2012
4 pages
2012 Global APTT Market Outlook: Test Volume Forecasts by Country and Market Segment
US$ 3,080.00
... APTT testing closer to the patient, creating additional opportunities and challenges for suppliers.This report presents a detailed analysis of the APTT testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as ...
April 2012
198 pages
2012 Global D-Dimer Market Outlook: Test Volume Forecasts by Country and Market Segment
US$ 3,080.00
... Dimer testing closer to the patient, creating additional opportunities and challenges for suppliers.This report presents a detailed analysis of the D-Dimer testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well ...
April 2012
197 pages
